Androgen receptor mutation (T877A) promotes prostate cancer cell growth and cell survival
暂无分享,去创建一个
S. Srivastava | Y. Shi | D. Mcleod | A. Dobi | L. Davis | Chen Sun | S Srivastava | Y Shi | D G McLeod | C Sun | L L Xu | C Nageswararao | L D Davis | T Segawa | A Dobi | T. Segawa | C. Sun | Linda L. Xu | L. Xu | C. Nageswararao | C. Sun | Leland D. Davis | Takehiko Segawa | David G. McLeod
[1] C. Arrowsmith. Structure and function in the p53 family , 1999, Cell Death and Differentiation.
[2] S. Balk,et al. Androgen receptor: A key molecule in the progression of prostate cancer to hormone independence , 2004, Journal of cellular biochemistry.
[3] H. Klocker,et al. Androgen receptor – an update of mechanisms of action in prostate cancer , 2000, Urological Research.
[4] J. Moul,et al. Alteration of the tumor suppressor gene p53 in a high fraction of hormone refractory prostate cancer. , 1995, The Journal of urology.
[5] G. Jenster,et al. A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to anti-androgens. , 1990, Biochemical and biophysical research communications.
[6] E. Gelmann,et al. Molecular biology of the androgen receptor. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[7] D. Tindall,et al. Androgen receptor signaling in androgen-refractory prostate cancer. , 2001, Journal of the National Cancer Institute.
[8] J. Moul,et al. Recombinant adenovirus vector expressing wild-type p53 is a potent inhibitor of prostate cancer cell proliferation. , 1995, Urology.
[9] E. Small. Update on the diagnosis and treatment of prostate cancer. , 1998, Current opinion in oncology.
[10] D. Feldman,et al. The development of androgen-independent prostate cancer , 2001, Nature Reviews Cancer.
[11] Martin R. Schneider,et al. Switch from antagonist to agonist of the androgen receptor blocker bicalutamide is associated with prostate tumour progression in a new model system , 1999, British Journal of Cancer.
[12] K. Tsui,et al. Down-regulation of the prostate specific antigen promoter by p53 in human prostate cancer cells. , 2004, The Journal of urology.
[13] T. Yanase,et al. A single amino acid substitution (Met786----Val) in the steroid-binding domain of human androgen receptor leads to complete androgen insensitivity syndrome. , 1992, The Journal of clinical endocrinology and metabolism.
[14] P. Chumakov,et al. Androgen regulates apoptosis induced by TNFR family ligands via multiple signaling pathways in LNCaP , 2005, Oncogene.
[15] C. Korch,et al. Molecular characterization of human prostate carcinoma cell lines , 2003, The Prostate.
[16] J. Veldscholte,et al. Stimulatory effects of antiandrogens on LNCaP human prostate tumor cell growth, EGF-receptor level and acid phosphatase secretion , 1990, The Journal of Steroid Biochemistry and Molecular Biology.
[17] M. Sadar,et al. Cell lines used in prostate cancer research: a compendium of old and new lines--part 2. , 2005, The Journal of urology.
[18] R. Vessella,et al. Molecular determinants of resistance to antiandrogen therapy , 2004, Nature Medicine.
[19] J. Thrasher,et al. Small-interfering RNA–induced androgen receptor silencing leads to apoptotic cell death in prostate cancer , 2005, Molecular Cancer Therapeutics.
[20] E. White,et al. Epothilone induced cytotoxicity is dependent on p53 status in prostate cells , 2004, The Prostate.
[21] H. Klocker,et al. Androgen receptor down regulation by small interference RNA induces cell growth inhibition in androgen sensitive as well as in androgen independent prostate cancer cells , 2005, The Journal of Steroid Biochemistry and Molecular Biology.
[22] M. Augustus,et al. Expression profile of an androgen regulated prostate specific homeobox gene NKX3.1 in primary prostate cancer. , 2000, The Journal of urology.
[23] Taylor Murray,et al. Cancer statistics, 1999 , 1999, CA: a cancer journal for clinicians.
[24] Michael Ittmann,et al. Mutation of the androgen receptor causes oncogenic transformation of the prostate. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[25] D. Yap,et al. mdm2: a bridge over the two tumour suppressors, p53 and Rb , 1999, Oncogene.